Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor.

Literature DB >> 31951492

Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor.

Daniel M Green¹.

Abstract

Entities: Disease

Mesh：

Year: 2020 PMID： 31951492 PMCID： PMC7048160 DOI： 10.1200/JCO.19.02479

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

× No keyword cloud information.

6 in total

1. Considerations in the Diagnosis and Management of Pediatric Patients With Favorable Histology Wilms Tumor Who Present With Only Pulmonary Nodules.

Authors: Daniel M Green
Journal: Pediatr Blood Cancer Date: 2015-12-02 Impact factor: 3.167

2. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.

Authors: David B Dix; Nita L Seibel; Yueh-Yun Chi; Geetika Khanna; Eric Gratias; James R Anderson; Elizabeth A Mullen; James I Geller; John A Kalapurakal; Arnold C Paulino; Elizabeth J Perlman; Peter F Ehrlich; Marcio Malogolowkin; Julie M Gastier-Foster; Elizabeth Wagner; Paul E Grundy; Conrad V Fernandez; Jeffrey S Dome
Journal: J Clin Oncol Date: 2018-04-16 Impact factor: 44.544

3. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases.

Authors: Daniel M Green
Journal: J Clin Oncol Date: 2018-09-13 Impact factor: 44.544

4. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.

Authors: David B Dix; Conrad V Fernandez; Yueh-Yun Chi; Elizabeth A Mullen; James I Geller; Eric J Gratias; Geetika Khanna; John A Kalapurakal; Elizabeth J Perlman; Nita L Seibel; Peter F Ehrlich; Marcio Malogolowkin; James Anderson; Julie Gastier-Foster; Robert C Shamberger; Yeonil Kim; Paul E Grundy; Jeffrey S Dome
Journal: J Clin Oncol Date: 2019-08-26 Impact factor: 44.544

5. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.

Authors: Paul E Grundy; Norman E Breslow; Sierra Li; Elizabeth Perlman; J Bruce Beckwith; Michael L Ritchey; Robert C Shamberger; Gerald M Haase; Giulio J D'Angio; Milton Donaldson; Max J Coppes; Marcio Malogolowkin; Patricia Shearer; Patrick R M Thomas; Roger Macklis; Gail Tomlinson; Vicki Huff; Daniel M Green
Journal: J Clin Oncol Date: 2005-08-29 Impact factor: 44.544

6. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.

Authors: Conrad V Fernandez; Elizabeth A Mullen; Yueh-Yun Chi; Peter F Ehrlich; Elizabeth J Perlman; John A Kalapurakal; Geetika Khanna; Arnold C Paulino; Thomas E Hamilton; Kenneth W Gow; Zelig Tochner; Fredric A Hoffer; Janice S Withycombe; Robert C Shamberger; Yeonil Kim; James I Geller; James R Anderson; Paul E Grundy; Jeffrey S Dome
Journal: J Clin Oncol Date: 2017-12-06 Impact factor: 44.544

6 in total

1 in total

1. Reply to D.M. Green.

Authors: David B Dix; Conrad V Fernandez; Yueh-Yun Chi; Lindsay A Renfro; Jeffrey S Dome Md
Journal: J Clin Oncol Date: 2020-01-17 Impact factor: 44.544

1 in total